Drug Trial Radar · NCT06434610
A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Jul 11, 2024
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Shanghai Jiaolian Drug Research and Development Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Shanghai Pharmaceuticals Holding Co., Ltd
- First posted
- May 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of B013 in patients with platinum-resistant recurrent ovarian cancer.
Conditions
- Platinum-resistant Recurrent Ovarian Cancer
Interventions
B013Drug
B013: The subjects will receive IV dose of B013 600 mg on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.
PaclitaxelDrug
Paclitaxel: 80 mg/m\^2 is administered weekly on Day 1, 8, 15 of each 28-day cycle.
PlaceboDrug
Placebo: The subjects will receive IV dose of placebo matched to B013 on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: Approximately 2 years
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China · Recruiting
The First Affiliated Hospital of Bengbu Medical University
Bengbu, China · Recruiting
XiangYa Hospital CentralSouth University
Changsha, China · Recruiting
Fujian Cancer Hospital
Fuzhou, China · Recruiting
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, China · Recruiting
Cancer Hospital of Shandong First Medical University
Jinan, China · Recruiting
Qilu Hospital of Shandong University
Jinan, China · Recruiting
Yunnan Cancer Hospital
Kunming, China · Recruiting
Guangxi Medical University Cancer Hospital
Nanning, China · Recruiting
Fudan University Shanghai Cancer center
Shanghai, China · Recruiting
The Obstetrics & Gynecology Hospital of Fudan University
Shanghai, China · Recruiting
The Second Hospital of Hebei Medical University
Shijiazhuang, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China · Recruiting
Shananxi Provincial Cancer Hospital
Xi'an, China · Recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, China · Recruiting
Yibin city second people's Hospital
Yibin, China · Recruiting
Henan Cancer Hospital
Zhengzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.